resTORbio Highlights Presentation Of Added Phase 2b Data For RTB101 At American Thoracic Society International Conference
(World News Science)

Cboe - Market News Story resTORbio Highlights Presentation Of Added Phase 2b Data For RTB101 At American Thoracic Society International Conference Benzinga Newsdesk 5/20/2019 7:56:52 AM resTORbio, Inc. (NASDAQ:TORC) today announced additional data from the Phase 2b clinical trial of RTB101, an orally administered, small molecule, potent inhibitor of target of rapamycin complex 1 (TORC1). RTB101 was well-tolerated and was observed to reduce the incidence of respiratory tract infections (RTIs) in patients 65 years of age and older at high risk of morbidity and mortality due...